ClinicalTrials.gg
RecruitingNCT07611903Updated Jul 15, 2026

HFNC Versus Microstream Advance Nasal Cannula for Oxygenation During ERCP

An interventional study of High-flow nasal canula and Microstream advance nasal cannula in Endoscopic Retrograde Cholangiopancreatography and Hypoxemia, sponsored by Kocaeli University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 84 Years. Per ClinicalTrials.gov, last updated 2026-07-15.

Sponsored by Kocaeli University · Not applicable, Interventional, and Supportive care

From the registry’s dates

  • Started Jul 2026; still recruiting 3 months later.
Phase
Not applicable
Study type
Interventional
Enrollment
74
Allocation
Randomized
Ages
18 Years to 84 Years
Sex
All
01

Study summary

Endoscopic retrograde cholangiopancreatography (ERCP) procedures are commonly performed under deep sedation and are associated with a risk of hypoxemia, particularly in prone or semi-prone positions. High-flow nasal cannula (HFNC) therapy may improve oxygenation by delivering heated and humidified oxygen at high flow rates, while the Microstream Advance nasal cannula provides simultaneous nasal oxygen delivery and oral oxygen insufflation.

This prospective randomized study aims to compare the effectiveness of HFNC and Microstream Advance nasal cannula in maintaining oxygenation during ERCP procedures. Patients undergoing ERCP will be randomized into two groups receiving either HFNC or Microstream Advance nasal cannula oxygen support during sedation.

The primary outcomes are the incidence of desaturation and oxygen reserve index (ORi) measurements during the procedure. Secondary outcomes include time to achieve target ORi levels, respiratory complications, and procedure-related adverse events.

02

Conditions studied

  • Endoscopic Retrograde Cholangiopancreatography
  • Hypoxemia

Browse trials for

03

In context

Hypoxia

1,076 studies on the registry are indexed under Hypoxia; 213 are open to participants now.

This study's planned enrollment of 74 is above the median of 45 across 769 interventional studies indexed under Hypoxia.

Browse Hypoxia studies →

Lead sponsor

Kocaeli University is the lead sponsor of 215 studies on the registry; 39 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 84 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients aged 18 to 84 years
  • I-III
  • Patients scheduled to undergo ERCP
  • Patients who provide written

Exclusion criteria

Exclusion Criteria:

  • Recent history of upper respiratory tract infection
  • History of lung cancer
  • Asthma
  • greater than 35 kg/m²
  • Refusal to participate in the study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
74 participants (estimated)

Study arms

  • Experimental
    HFNC Group

    Participants receive oxygen support with high-flow nasal cannula (HFNC) during ERCP under sedation.

    Device: High-flow nasal canula

  • Active comparator
    Microstream Advance Nasal Cannula Group

    Participants receive oxygen support with Microstream Advance nasal cannula during ERCP under sedation.

    Device: Microstream advance nasal cannula

Interventions

  • DeviceHigh-flow nasal canula

    Heated and humidified high-flow oxygen therapy delivered through a nasal cannula during ERCP under sedation

  • DeviceMicrostream advance nasal cannula

    Oxygen support delivered through the Microstream Advance nasal cannula during ERCP under sedation.

06

What researchers measure

Primary outcomes

  1. Incidence of Desaturation During ERCP

    Comparison of the frequency of oxygen desaturation episodes between HFNC and Microstream Advance nasal cannula groups during ERCP under sedation.

    Time frame: During the ERCP procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07611903
Lead sponsor
Kocaeli University
Responsible party
Volkan Alparslan (Assistant Professor, Kocaeli University) — Principal investigator
First posted
May 28, 2026
Start date
Jul 14, 2026
Primary completion
Nov 30, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Jul 15, 2026

Study contacts

Volkan Alparslan, M.D.
Contact
volknn@hotmail.com
05059374578
Volkan Alparslan, M.D.
principal investigator · Kocaeli University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion